Abcuro has successfully closed a $66 million Series D financing round, a follow-on to previous funding, led by New Leaf Venture Partners with participation from existing investors like abrdn and Bain Capital Life Sciences. This capital infusion will accelerate the development of their autoimmune disease therapies, specifically advancing their lead candidate, ABC008, into later-stage clinical trials. The company plans to utilize these funds to further expand their pipeline and potentially scale their operations.